91 related articles for article (PubMed ID: 20222793)
1. Clinical application of breast cancer risk assessment models.
Ready K; Litton JK; Arun BK
Future Oncol; 2010 Mar; 6(3):355-65. PubMed ID: 20222793
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
3. [Risk assessment for familial occurrence of breast cancer].
Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T
Zentralbl Gynakol; 1995; 117(8):423-34. PubMed ID: 7571905
[TBL] [Abstract][Full Text] [Related]
4. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
6. [Estimation of individual breast cancer risk: relevance and limits of risk estimation models].
De Pauw A; Stoppa-Lyonnet D; Andrieu N; Asselain B
Bull Cancer; 2009 Oct; 96(10):979-88. PubMed ID: 19744918
[TBL] [Abstract][Full Text] [Related]
7. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of hereditary risk in a mammography population.
Jones JL; Hughes KS; Kopans DB; Moore RH; Howard-McNatt M; Hughes SS; Lee NY; Roche CA; Siegel N; Gadd MA; Smith BL; Michaelson JS
Clin Breast Cancer; 2005 Apr; 6(1):38-44. PubMed ID: 15899071
[TBL] [Abstract][Full Text] [Related]
10. [Breast cancer screening different from that used for the general population: who is concerned and with which approach?].
Chappuis PO
Rev Med Suisse; 2006 May; 2(66):1296-8, 1301-2, 1304-5. PubMed ID: 16775990
[TBL] [Abstract][Full Text] [Related]
11. BRCA and beyond: a genome-first approach to familial breast cancer risk assessment.
Trainer AH; Thompson E; James PA
Discov Med; 2011 Nov; 12(66):433-43. PubMed ID: 22127114
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing by cancer site: breast.
Shannon KM; Chittenden A
Cancer J; 2012; 18(4):310-9. PubMed ID: 22846731
[TBL] [Abstract][Full Text] [Related]
13. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?
Jacobi CE; de Bock GH; Siegerink B; van Asperen CJ
Breast Cancer Res Treat; 2009 May; 115(2):381-90. PubMed ID: 18516672
[TBL] [Abstract][Full Text] [Related]
14. 18. Genetics of breast cancer.
Irving M; Elmslie F; Berg J
Int J Clin Pract; 2002 Nov; 56(9):677-82. PubMed ID: 12469982
[TBL] [Abstract][Full Text] [Related]
15. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
16. Models of genetic susceptibility to breast cancer.
Antoniou AC; Easton DF
Oncogene; 2006 Sep; 25(43):5898-905. PubMed ID: 16998504
[TBL] [Abstract][Full Text] [Related]
17. Considerations in genetic counseling for inherited breast cancer predisposition.
Robson ME; Offit K
Semin Radiat Oncol; 2002 Oct; 12(4):362-70. PubMed ID: 12382194
[TBL] [Abstract][Full Text] [Related]
18. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
[TBL] [Abstract][Full Text] [Related]
20. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
